Brief: Veracyte Q3 Revenue USD 90.1 Million Vs. IBES Estimate USD 84.4 Million
07/11/2023 21:05
Nov 07 (Reuters) - Veracyte Q3 gross margin 64%. * Q3 net income USD -29.6 million * outlook FY revenue USD 352-354 million * outlook FY revenue growth 19%
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina